ConductScience.org, home

Paper282922

Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).

Cunningham I and 9 others. Blood, 1979. Cited by 248 papers, by iCite.

Cite this record

ConductScience Library. Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Papers, record 282922. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/282922

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).
PubMed
Journal
Blood
PubMed
Year
1979
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
248
iCite
Relative citation ratio, by iCite
7.78
iCite
Revised in PubMed
2021-02-16
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cunningham II
2Gee TT
3Dowling MM
4Chaganti RR
5Bailey RR
6Hopfan SS
7Bowden LL
8Turnbull AA
9Knapper WW
10Clarkson BB

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Chromosomes, Human, 21-22 and YMajor topic
Leukemia, MyeloidMajor topic
Adolescent
Adult
Asparaginase
Cell Transformation, Neoplastic
Cytarabine
Female
Humans
Hydroxyurea
Male
Middle Aged
Radiography
Spleen
Splenectomy
Thioguanine

Source PubMed

Download CSV of topics

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 248 citations.

PMIDTitleJournalYearIn PapersSource
17882283The history of myeloproliferative disorders: before and after Dameshek.Leukemia2008https://conductscience.org/library/papers/17882283PubMed
17031690High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study.Ann Hematol2007https://conductscience.org/library/papers/17031690PubMed
12835715Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.Leukemia2003https://conductscience.org/library/papers/12835715PubMed
11551022Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.Bone Marrow Transplant2001https://conductscience.org/library/papers/11551022PubMed
9643527Treatment of chronic myelogenous leukaemia.Med Oncol1998https://conductscience.org/library/papers/9643527PubMed
7929813Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.J Clin Invest1994https://conductscience.org/library/papers/7929813PubMed
7003128Chemotherapy of the myeloid leukaemias.J R Coll Physicians Lond1980https://conductscience.org/library/papers/7003128PubMed
6938261Buffy coat autografts for patients with chronic granulocytic leukaemia in transformation.Blut1981https://conductscience.org/library/papers/6938261PubMed
6751438Allogeneic marrow transplantation for chronic granulocytic leukemia.Blut1982https://conductscience.org/library/papers/6751438PubMed
6108135Haemopoietic stem cell autografts for leukaemia.Blut1980https://conductscience.org/library/papers/6108135PubMed
3459595Treatment of blastic transformation of chronic myelogenous leukemia with mitoxantrone.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3459595PubMed
3277680Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.Blut1988https://conductscience.org/library/papers/3277680PubMed
3196882Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.Blut1988https://conductscience.org/library/papers/3196882PubMed
3166389Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Treatment results of 69 patients.Blut1988https://conductscience.org/library/papers/3166389PubMed
3121203Treatment of acute myeloid leukemia and blastic phase of chronic myeloid leukemia with combined eflornithine (alpha difluoromethylornithine) and methylglyoxal-bis-guanyl hydrazone (methyl-GAG).Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3121203PubMed
2350591Restoration of nonclonal hematopoiesis in chronic myelogenous leukemia with interferon alpha.Blut1990https://conductscience.org/library/papers/2350591PubMed
2312599Chronic myelogenous leukemia: an overview.J Cancer Res Clin Oncol1990https://conductscience.org/library/papers/2312599PubMed
1803180Eradication of leukaemic marrow and prevention of leukaemia relapse with total body irradiation and bone marrow transplantation.Med Oncol Tumor Pharmacother1991https://conductscience.org/library/papers/1803180PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/282922

GET https://conductscience.org/api/papers/v1/282922/authors